Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

NovaBay Pharmaceuticals Q2 EPS $(1.37) Misses $(1.23) Estimate, Sales $2.40M Miss $3.15M Estimate

Author: Benzinga Newsdesk | August 13, 2024 04:06pm
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.23) by 11.38 percent. This is a 96.92 percent increase over losses of $(44.43) per share from the same period last year. The company reported quarterly sales of $2.40 million which missed the analyst consensus estimate of $3.15 million by 23.81 percent. This is a 32.09 percent decrease over sales of $3.53 million the same period last year.

Posted In: NBY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist